ProQR Therapeutics
Business Services · Netherlands · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Zernikedreef 9, Leiden, South Holland, 2...Phone Number
+31 881667000Website
www.proqr.comRevenue
$18.2 MillionStock Symbol
PRQRIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
2
1
1
1
1
About ProQR Therapeutics
ProQR Therapeutics is a biotechnology company founded in 2012 and headquartered in Leiden, Netherlands. The company specializes in researching, developing, and manufacturing RNA-based therapies focused on treating severe genetic rare diseases. As a publicly traded company, ProQR Therapeutics utilizes advanced scientific approaches to create innovative therapeutic solutions for patients with limited treatment options. The company maintains a strong focus on research and development within the pharmaceutical and biotechnology sectors, with operations spanning both Europe and North America.Explore more
ProQR Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ProQR Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once ProQR Therapeutics has new funding data
Check out if ProQR Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Check if ProQR Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on ProQR Therapeutics recently announced quarterly report
ProQR Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if ProQR Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at ProQR Therapeutics
Product Launch: Get notified when ProQR Therapeutics launches new products
Recommended Actions
Reach out to Masked Content who joined ProQR Therapeutics as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
ProQR Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
ProQR Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about ProQR Therapeutics.
ProQR Therapeutics financials insights
Gather financial insights about ProQR Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Stock Offering
$97.5M
2020
Debt
$30M
2022
Other Financing Round
$75M
2024
Other Financing Round
$8.1M
ProQR Therapeutics Tech Stack
A closer look at the technologies used by ProQR Therapeutics
Most Recent Scoops
Open Position
Left Company
Executive Move
Executive Moves, Left Company
Project
ProQR Therapeutics has announced that initial safety data for AX-0810 is expected to be available towards the end of the year, with target engagement data to be presented in the first half of next year.
Medical Research, Pharmaceuticals, Clinical Operations
Project
ProQR Therapeutics has announced that its lead program AX-0810, targeting NTCP for the treatment of cholestatic diseases, has received CTA approval and is starting a target engagement first-in-human trial.
Product Development, Compliance, Medical Research, Pharmaceuticals
Project
Medical Research, Pharmaceuticals, Clinical Operations
ProQR Therapeutics News & Media
ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform
LEIDEN, Netherlands & CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR or the Company), a clinical-stage biotechnology company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced positive target engagement data from its ongoing Phase 1 clinical study evaluating AX-0810, the Company’s first investigational Axiomer RNA editing oligonucleotide (EON), in heProQR Announces First Quarter 2026 Operating and Financial Results
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today reported its financial and operating results for the quarter ended March 31, 2026, and provided a business update.ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing Platform
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced presentations at several upcoming scientific conferences, highlighting continued progress in the application of its Axiomer RNA editing platform.ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the Annual General Meeting (AGM) of Shareholders will take place on Tuesday, June 2, 2026 at 1500 CEST at the offices of Allen Overy Shearman Sterling LLP, in Amsterdam, the Netherlands.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding ProQR Therapeutics
Sign Up For FreeTo access detailed company insights
ProQR Therapeutics is a biotechnology company founded in 2012 and headquartered in Leiden, Netherlands. The company specializes in researching, developing, and manufacturing RNA-based therapies focused on treating severe genetic rare diseases. As a publicly traded company, ProQR Therapeutics utilizes advanced scientific approaches to create innovat... Read More
